Skip to content

Efficacy Rate of Unipolar Polarity Switch for Lesion Assessment in Pulmonary Vein Isolation

To Assess the Efficacy Rate of Unipolar Polarity Switch for Lesion Assessment in Pulmonary Vein Isolation

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05464537
Enrollment
8
Registered
2022-07-19
Start date
2023-08-28
Completion date
2024-11-27
Last updated
2025-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Brief summary

The technique of intraprocedural electrogram morphology as a measure of lesion effectiveness in an attempt to achieve durable PVI, clearly led to shortened procedural time, radiation exposure, and superiority in outcomes, with the implementation of a reproducible, readily available intraprocedural tool that can be applied universally.

Detailed description

One initial study reported that unipolar atrial EGM modification was a useful end point for RF energy delivery. They compared 2 groups of patients with paroxysmal AF undergoing PVI facilitated by an electroanatomic mapping system, merged preprocedural LA computed tomographic scan, and a circular mapping catheter. They were the first to use intraprocedural electrogram morphology as a measure of lesion effectiveness in an attempt to achieve durable PVI. The technique, clearly led to shortened procedural time, radiation exposure, and superiority in outcomes, with the implementation of a reproducible, readily available intraprocedural tool that can be applied universally. As there is scant data is this area with lack of randomized human trials, planned on building and further validating evidence from Bortone et al in demonstrating that loss of unipolar negative component during PVI can serve a great adjuvant tool for achieving durability of PVI with overall lesser procedural time and no significant increase in adverse events.

Interventions

OTHERUnipolar Polarity Switch Left

10-15 Left veins are randomized to Unipolar Polarity Shift, right veins are randomized to CAI-OPR-LAAP

OTHERUnipolar Polarity Switch Right

10-15 cases randomized to CAI-OPR-LAAP on left veins, and Unipolar Polarity Switch on right veins

Sponsors

Kansas City Heart Rhythm Institute, Overland Park, KS
CollaboratorUNKNOWN
Kansas City Heart Rhythm Research Foundation
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All Patients ≥ 18 years of age * Undergoing pulmonary vein isolation for De-Novo Atrial Fibrillation.

Exclusion criteria

* Patients unable to give consent * Who do not have De-novo AF.

Design outcomes

Primary

MeasureTime frameDescription
Images comparing PURE EP unipolar signals against Claris unipolar signals1 dayObserve if the quality of PURE EP's unipolar signals are acutely and better suited for lesion assessment? This outcome compares mapping images with site of activation to the PURE EP electrogram and compare if they correspond to each other.
Number of patients with Pericardial Effusion1 yearNumber of patients with intraprocedural and post procedure adverse events and serious adverse events - Pericardial Effusion
Number of patients with need for open heart surgery1 yearNumber of patients with intraprocedural and post procedure adverse events and serious adverse events - need for open heart surgery
Number of patients with phrenic nerve injury1 yearNumber of patients with intraprocedural and post procedure adverse events and serious adverse events - phrenic nerve injury
Number of patients with pulmonary vein stenosis1 yearNumber of patients with intraprocedural and post procedure adverse events and serious adverse events - pulmonary vein stenosis
Esophageal Temp max (existing protocol)1 dayEsophageal temp max (existing protocol)
Esophageal Time above threshold1 dayEsophageal Time above threshold
Esophageal Time to return to baseline1 dayEsophageal Time to return to baseline
Efficacy rate of loss of unipolar negative componentProcedure day and 12 month follow-up dayObserve the efficacy rate of loss of unipolar negative component in isolation of the Pulmonary Veins. Loss of unipolar negative component will be assessed during the Radiofrequency ablation procedure. The durability of Pulmonary vein isolation will be assessed at 12 month follow up, if there is recurrence of Atrial fibrillation.
Number of patients with Esophageal Injury1 yearNumber of patients with intraprocedural and post procedure adverse events and serious adverse events - Esophageal Injury
Number of patients with TIA/CVA1 yearNumber of patients with intraprocedural and post procedure adverse events and serious adverse events - transient ischemic attack/Cerebrovascular accident (TIA/CVA)
Number of patients with Bleeding/Hematoma1 yearNumber of patients with intraprocedural and post procedure adverse events and serious adverse events - Bleeding/Hematoma

Secondary

MeasureTime frameDescription
Total RF Time1 dayTotal RF Time in pulmonary veins with Unipolar polarity switch as endpoint vs. CAI-OPR-LAAP
Discrimination with High Frequency Algorithm as a confirmation tool1 dayIn Left Superior Vein, Right Superior Vein, and Right Inferior Vein, validate Near Field and Far Field Discrimination with High Frequency Algorithm as a confirmation tool (Visitag #'s annotated into PURE EP)
6-month freedom from AF6 months6-month freedom from AF
Redo's within 1 year1 yearRedo's within 1 year which vein randomized group reconnected
Location of Catheter tip1 dayLocation of Catheter tip (LSPV, RSPV, RIPV, LIPV, LAA, Other) (carto image)
Duration of HFA channel compared to Bipolar1 dayDuration of HFA channel compared to Bipolar, Was there both a near and far field component?
Compare 1st pass isolation1 dayCompare 1st pass isolation in the Unipolar polarity switch group to Carto's Ablation Index per Overland Park Regional's Left Atrial Ablation Protocol (CAI-OPR-LAAP)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026